Tavapadon Lessens Motor Symptoms in Patients with Early-stage Parkinson’s, Phase 2 Trial Finds

[Farooqji]

parkinsonsnewstoday.com/201...

[francis6]

Encouraging, thanks for posting.

[sharoncrayn]

IQ:

The study was terminated EARLY. So much for that drug.

Sharon

[Farooqji in reply to sharoncrayn]

Preparations are underway to start phase 3 in 2020

neurologytimes.com/article/...

[sharoncrayn in reply to Farooqji]

Obviously my mistake or the person who wrote what I read. I thought I had read it was terminated early, but obviously not so from the press release.

[sharoncrayn in reply to Farooqji]

IQ:

This is the problem I was referring to with this drug.

So how did they obfuscate these early results to continue on with another clinical trial? A lack of efficacy in one clinical trial apparently doesn't matter.

Difficult not to be cynical about some of these trials.

"Although a previous study of tavapadon (NCT02687542) was terminated early due to lack of efficacy in moderate to advanced Parkinson’s, the “favorable profile of tavapadon in clinical studies to date” support its potential “both as a monotherapy for patients with early-stage disease and as an adjunct to levodopa for patients with late-stage disease,” said Raymond Sanchez, MD, chief medical officer at Cerevel (which was launched by Pfizer and Bain Capital in October 2018)."